Overview
- Carl Zeiss Meditec, which on Tuesday reported weaker half-year results, launched a three-year cost program that could affect up to 1,000 roles worldwide.
- Revenue fell 5.7% to €991 million, adjusted EBITA dropped to €60.5 million, and net income slid to €13.3 million for the first half.
- The plan includes pruning weaker products, reworking supply chains, and moving some work to lower-cost countries, with production in China and other Asian sites set to grow as site-level decisions are still to be negotiated with employee representatives.
- Management expects up to €150 million in one-off restructuring costs over three years and is targeting more than €200 million in yearly improvements by fiscal 2028/29.
- Investors sent the shares down more than 3% after leadership cut full-year targets to €2.15–€2.2 billion in sales and an 8%–10% operating margin with at least €50 million in special charges.